Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Clinical trial NCT05738694 · RECRUITING
Trial details
- NCT number
- NCT05738694
- Sponsor
- ZHOU FANGJIAN
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-19
- Primary completion
- 2027-12-31
- Enrollment
- 298
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.